Individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion, ASCO and Friends of Cancer Research (Friends) asserted in a recently released joint position statement.
To date, clinical trials for COVID-19 vaccines have almost universally excluded patients with cancer, and many have excluded those who have a history of cancer. Because these studies enrolled narrower, more homogeneous patient populations, many of the most vulnerable patients—who have comorbidities and, in some cases, have compromised immune function—do not know whether the vaccines are safe or effective for them. Especially now that multiple vaccines have been authorized for emergency use by the U.S. Food and Drug Administration and other national entities, ASCO and Friends say eligibility should be immediately expanded to include patients with cancer as the default.
Everett E. Vokes, MD, FASCO
“We’ve learned that patients with cancer are especially vulnerable to severe illness, hospitalization, or death due to COVID-19,” said ASCO President Everett E. Vokes, MD, FASCO. “However, since clinical trials for COVID-19 vaccines have largely excluded patients with cancer, we still have a long way to go to better understand how safe and effective COVID-19 vaccines are for patients in active treatment. It is critically important to study adequate numbers of patients who have cancer or a history of cancer so that we can better understand the degree to which patients with cancer, various kinds of immunocompromise, or both respond to vaccines.”
ASCO and other professional organizations recommend patients across the cancer continuum receive vaccinations (including for COVID-19) unless specifically contraindicated, such as evidence of potential risk to patient safety. This recommendation is currently based, however, on consensus expert opinion in the absence of clinical evidence. There is a lack of understanding of the degree of immunity and clinical protection that COVID-19 vaccines provide in individuals with compromised immune systems. Until studies provide more specific insights about populations with cancer, patients with cancer who are vaccinated are encouraged to continue to follow all guidance on masking and physical distancing to reduce any potential exposure to SARS–CoV-2.
Jeff Allen, PhD
“We continue to emphasize that broadening eligibility criteria to clinical trials will help inform the optimal use of new medicines for more people, and the same principles apply to COVID-19 vaccines,” said Jeff Allen, PhD, President and Chief Executive Officer of Friends. “Because people with cancer are at greater risk for severe outcomes from COVID-19, we urge manufacturers and trial sponsors to enroll patients with cancer and develop studies specifically geared toward patients with cancer to fully characterize the level of protection these important vaccines provide.”
In the new joint position statement, ASCO and Friends offered the following recommendations:
- Vaccine trial sponsors should design studies to be as broadly inclusive as possible. Existing and future COVID-19 vaccine trials should exclude people with cancer (current or history of) and/or people who are immunocompromised only if there is specific and credible risk of harm to them from trial participation.
- Vaccine manufacturers and trial sponsors should prioritize recruitment of patients with cancer through partnerships with oncology practices, cancer centers, and academic medical centers. COVID-19 vaccine trials should be prospectively designed and purposefully recruit individuals with cancer from diverse populations and age groups to enable valid subset analysis.
- Government agencies with oversight of vaccine development and review should encourage and incentivize vaccine manufacturers to include patients with cancer in existing and future COVID-19 vaccine trials.
- Public health agencies and other research organizations should design, collect, and analyze real-world data on vaccine effectiveness in patients with cancer, in addition to clinical research data. For populations underrepresented in prior vaccine trials, this data collection would enable the most comprehensive understanding of practical clinical considerations.
Read the full position statement at asco.org/sites/new-www.asco.org/files/content-files/blog-release/pdf/2021-ASCO-Friends-Vaccine-Trials-Position-Statement.pdf.
© 2021. American Society of Clinical Oncology. All rights reserved.
